In Japan, Leukine is branded as Sargmalin and was licensed to Nobelpharma in 2022 for certain indications.
Leukine is a glycosylated recombinant human GM-CSF produced by recombinant DNA technology in yeast.
Partner Therapeutics will execute the manufacturing of Sargmalin for Nobelpharma at its facility in Lynnwood, US.
See Also:
GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval
Preview
来源: Pharmaceutical Technology
UK MHRA approves Advanz Pharma antibiotic for complex infections
Preview
来源: Pharmaceutical Technology
The approval is based on the findings from the multicentre, randomised, double-blind, placebo-controlled Phase II PAGE study.
It assessed Leukine in 64 subjects with mild to moderate aPAP.
Subjects were randomised in a 1:1 ratio to receive either Leukine 125μg or a placebo twice a day for seven days, followed by seven days off, over 12 cycles of two weeks.
The trial demonstrated a significant improvement on the primary endpoint, which was the improvement in the alveolar-arterial oxygen gradient from baseline to week 25.
Partner Therapeutics CEO Robert Mulroy stated: “We are grateful to Nobelpharma for their partnership, as well as their deep commitment to making this treatment available to aPAP patients in Japan.
“It has been a pleasure working with their team and we look forward to ensuring the availability of Sargmalin. We also deeply appreciate the commitment of the many patients and doctors who participated in the investigator-initiated clinical trial led by Dr Nakata of Niigata University.”